Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Aug
31
Today In Oncology
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country
Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo